PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Both companies show declining cash positions (-15.30% vs GNPX's -56.88%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half of GNPX's -56.88%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
Below half of GNPX's -51.70%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-12.74%
Similar yoy growth to GNPX's -11.65%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Less than half of GNPX's 35.69%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.64%
Below half of GNPX's 23.09%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
≥ 1.5x GNPX's -0.57%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
72.22%
Similar yoy growth to GNPX's 73.26%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Less than half of GNPX's 527.38%. David Dodd sees fewer expansions in other current obligations.
32.21%
Less than half of GNPX's 110.23%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Less than half of GNPX's 110.23%. David Dodd sees far fewer liability expansions relative to competitor.
0.06%
Less than half of GNPX's 3201.69%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
0.75-0.9x GNPX's -3.97%. Bill Ackman questions if competitor reinvests profits more robustly.
0.51%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half GNPX's -50.82%. Michael Burry sees potential underperformance in building shareholder capital.
-15.58%
≥ 1.5x GNPX's -0.57%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of GNPX's 110.36%. David Dodd sees better deleveraging or stronger cash buildup than competitor.